Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

PHASE4TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

August 13, 2021

Study Completion Date

August 13, 2021

Conditions
Gout Attack
Interventions
DRUG

Etanercept

Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2

DRUG

Triamcinolone Acetonide

Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2

Trial Locations (1)

08901

Rutgers, Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER

NCT03636373 - Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout | Biotech Hunter | Biotech Hunter